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Potassium Channel Interacting 
Protein 2 (KChIP2) is not a 
transcriptional regulator of cardiac 
electrical remodeling
Sine V. Winther1, Tomi Tuomainen2, Rehannah Borup3, Pasi Tavi2, Gudrun Antoons4 & 
Morten B. Thomsen1
The heart-failure relevant Potassium Channel Interacting Protein 2 (KChIP2) augments CaV1.2 and 
KV4.3. KChIP3 represses CaV1.2 transcription in cardiomyocytes via interaction with regulatory DNA 
elements. Hence, we tested nuclear presence of KChIP2 and if KChIP2 translocates into the nucleus 
in a Ca2+ dependent manner. Cardiac biopsies from human heart-failure patients and healthy donor 
controls showed that nuclear KChIP2 abundance was significantly increased in heart failure; however, 
this was secondary to a large variation of total KChIP2 content. Administration of ouabain did not 
increase KChIP2 content in nuclear protein fractions in anesthetized mice. KChIP2 was expressed in 
cell lines, and Ca2+ ionophores were applied in a concentration- and time-dependent manner. The cell 
lines had KChIP2-immunoreactive protein in the nucleus in the absence of treatments to modulate 
intracellular Ca2+ concentration. Neither increasing nor decreasing intracellular Ca2+ concentrations 
caused translocation of KChIP2. Microarray analysis did not identify relief of transcriptional repression 
in murine KChIP2−/− heart samples. We conclude that although there is a baseline presence of KChIP2 
in the nucleus both in vivo and in vitro, KChIP2 does not directly regulate transcriptional activity. 
Moreover, the nuclear transport of KChIP2 is not dependent on Ca2+. Thus, KChIP2 does not function as 
a conventional transcription factor in the heart.
Heart failure is a disease of the elderly1, and the prevalence is rising both in Western and developing countries 
following the general longer lifespan2. Heart failure is characterized by decreased pump efficiency leading to 
symptoms like shortness of breath, edema and fatigue. Besides the left ventricular structural remodeling seen 
in HF2, electrophysiological modifications are taking place as well. The most dominant electrophysiological 
changes in heart failure are modulations of repolarizing ion currents prolonging the cardiac action potential3–6 
and changes in the intracellular Ca2+ handling7,8 aiming to improve cardiac pump function, but as a byproduct 
the electrical remodeling creates a substrate for ventricular arrhythmias. Underlying these structural and elec-
trophysiological remodeling processes lie a range of transcriptional alterations where the regulating mechanisms 
are largely unknown9.
Potassium Channel Interacting Proteins (KChIPs) are accessory β-subunit proteins belonging to a family of 
small Ca2+-binding cytosolic proteins consisting of four isoforms, KChIP1-4. KChIP1-3 are structurally related 
as they all contain a highly conserved C-terminal core region of approximately 180 amino acids that house the 4 
EF-hand domains capable of binding Ca2+ ions which induces a conformational change in the protein10. These 
3 isoforms share a common mode of action on potassium channel kinetics: They all increase peak KV4 current, 
slow channel inactivation and quickens the recovery from inactivation. All isoforms are expressed in brain, but 
KChIP2 is the only isoform expressed in the heart, where it regulates both the repolarizing KV4.3 current4,11,12 
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and the depolarizing CaV1.2 current8,13–15. The heightened interest of KChIP2 comes from its reported downreg-
ulation in HF16,17, which is thought to contribute to the modified repolarization and altered Ca2+ handling in the 
disease.
It has been shown that KChIP3 besides its electrophysiological effects also holds properties that affect 
gene transcription. KChIP3, primarily expressed in brain tissue11,18, has also independently been identified as 
Downstream Regulatory Element Agonist Modulator (DREAM)19 and as calsenilin20. KChIP3 translocates from 
the cytosol to the nucleus upon a raise in cytosolic Ca2+ concentration following activation of a calmodulin 
kinase II (CaMKII) mediated pathway21. In the nucleus, KChIP3 only binds DNA in a Ca2+-free state, whereas 
binding of Ca2+ to KChIP3 leads to conformational changes preventing binding to DNA19,22. KChIP3 binds 
Downstream Regulatory Elements (DRE) on the DNA and represses transcription of several genes, including 
Na+/Ca2+ exchanger 3 in cerebellar neurons22, prodynorphin, involved in pain sensation19,23, and CaV1.2 channel 
in neonatal rat cardiomyocytes21.
It has been shown that in addition to KChIP3, the other KChIP isoforms bind DRE sites24, so based on this and 
the structural familiarity between KChIP2 and KChIP3, we investigated whether KChIP2 have transcriptional 
regulatory functions. If KChIP2 proves to be transcriptionally active, the repression of KChIP2-controlled genes 
would potentially be lost in HF as a result of the downregulation of the protein. At the same time, an increase in 
the intracellular Ca2+ concentration seen in HF would promote translocation of KChIP2 from the cytosol to the 
nucleus. In the present study, we investigated whether KChIP2 can translocate from the cytosol to the nucleus and 
tested whether KChIP2 binds DNA and alters gene expression.
Results
KChIP2 expression and localization in human failing and healthy hearts. Heart failure is a disease 
characterized by an elevated adrenergic state, resulting in an chronic increased intracellular Ca2+ concentration25, 
suggesting that the nuclear fraction of KChIP2 could be increased in this disease. Tissue samples were obtained 
from hearts from heart-failure patients with an ejection fraction of 22 ± 9% (n = 5) and from healthy hearts 
(ejection fraction 66 ± 2%; n = 5, p < 0.05; Table 1). We found that total protein levels were comparable in human 
samples from failing and non-failing cardiac tissue. KChIP2 migrated as a single band to the expected size around 
32 kDa on immunoblots (Fig. 1A). We observed comparable total KChIP2 levels in human non-failing and failing 
heart samples; although there was a trend towards increased total KChIP2 levels in samples from failing hearts 
(P = 0.064; Fig. 1B). Successful separation of nuclear and cytosolic fractions was confirmed by the presence of 
Lamin A/C in nuclear fractions only (Fig. 1C). KChIP2 was present in both cytosolic and nuclear fractions, but 
the nuclear KChIP2 content was significantly larger in failing hearts relative to non-failing hearts (P = 0.025; 
Fig. 1D). Notwithstanding, the difference in nuclear KChIP2 content seemed to be dependent on the non-signif-
icant change in total KChIP2, since the nuclear-to-total KChIP2 ratio was comparable in failing and non-failing 
hearts (P = 0.6). Hence, in human hearts, KChIP2 is present in the nucleus; however, the nuclear-to-cytosolic 
ratio is not altered in end-stage heart failure.
Nuclear translocation in vivo. Next, we investigated whether it is possible to induce a KChIP2 trans-
location process into the nucleus in cardiomyocytes in vivo. Mice were injected with a range of pharma-
cological compounds increasing the heart rate and/or inotropic state and thereby the intracellular Ca2+ 
concentration26, with the aim of initiating an acute KChIP2 translocation to the nucleus (Fig. 2A). Mice 
treated with adrenaline and caffeine showed an increase of nuclear KChIP2 in cardiomyocytes compared to 
controls in most experiments, e.g., Fig. 2B; however not consistently. Ouabain, isoprenaline and dobutamine 
had no consistent effect on KChIP2 localization, e.g. the nuclear-to-cytosolic ratios of KChIP2 after adminis-
tration of saline or ouabain were comparable (Fig. 2C,D). Generally, the variation between the translocation 
responses in the treated mice was large and the outcomes did not relate to the chronotropic or inotropic 
Heart failure Non-failing controls P value
Age, years 59 ± 2 59 ± 4 0.91
Body-mass index 26 ± 1 28 ± 5 0.79
Ejection fraction, % 22 ± 9 66 ± 2 0.0003
Dilated cardiomyopathy 5/5 0/5 0.008
NYHA class III 5/5 0/5 0.008
Medication
 Beta-adrenergic receptor blockers 3/5 0/5 0.17
 Anticoagulation 5/5 1/5 0.048
 ACE-inhibitors 5/5 0/5 0.008
 Digoxin 3/5 0/5 0.17
 Diuretics 4/5 1/5 0.21
Table 1.  Characteristics of patients from which cardiac biopsy material were used for immunoblotting. 
P values for age, body-mass index and ejection fraction derive from unpaired Student’s t-tests. Data on dilated 
cardiomyopathy, New York Heart Associations (NYHA) class III and medications are provided as number of 
patients relative to group size (5 patients in each group); these P values are from comparisons using Fisher’s 
exact test.
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effects of the pharmacological compounds. Overall, we did not identify statistically significant KChIP2 trans-
location based on the pharmacologically induced acute elevation of intracellular Ca2+ in vivo.
Figure 1. KChIP2 expression and subcellular localization in human hearts. (A) Representative 
immunoblots showing detection of KChIP2 in cytosolic (C) and nuclear (N) protein fractions from heart 
samples from heart-failure (HF; n = 3) and non-failing (NF; n = 2) patients. Lanes with molecular weight 
marker are indicated with M. Arrowheads indicate KChIP2 and β-tubulin bands in the upper and lower 
panel, respectively. The double band of lamin A/C is indicated with a “{”. Detecting β-tubulin and Lamin 
A/C confirms equal loading of cytosolic protein and successful fractionation, respectively. Each sample is 
analyzed in duplicate. (B) Quantification of the total amount of KChIP2 in the two experimental groups. 
(C) Quantification of Lamin A/C in nuclear and cytosolic fractions. (D) Ratio of the nuclear KChIP2 and 
nuclear Lamin A/C in NF and HF samples (*P = 0.025). (E) Ratio of the nuclear KChIP2 to total KChIP2. 
P values from Student’s t test.
www.nature.com/scientificreports/
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Nuclear translocation in vitro. To directly visualize the subcellular localization of KChIP2 and determin-
ing if an increase in the intracellular Ca2+ concentration is a triggering factor for translocation from the cytosol 
to the nucleus, KChIP2-transfected cells were treated in a time- and concentration dependent manner with Ca2+ 
ionophores (Fig. 3). The transfected cells, in absence of treatments to elevate the intracellular Ca2+ concentration, 
had already significant levels of KChIP2-immunoreactive protein in the nucleus (Fig. 3A). Increasing the intra-
cellular Ca2+ concentration caused no change in nuclear levels of KChIP2 (Fig. 3C). Comparable results were 
obtained when treating the cells with another Ca2+ ionophore (A23187, data not shown).
Figure 2. KChIP2 expression and subcellular localization in mouse hearts. (A) Representative two lead 
surface ECG from anesthetized mice at baseline and after treatment with 1 mg/g ouabain IP. (B) Exemplary 
immunoblots showing an increase of KChIP2 in the nuclear fraction when the mouse was treated with 
adrenaline and caffeine (A + C). Saline (S) treated mice served as controls. (C) Representative immunoblots 
showing the cytosolic (C) and nuclear (N) content of KChIP2 after administration of ouabain, isoprenaline and 
dobutamine, all increasing heart rate and inotropy, and saline as control. (D) Quantification of the nuclear-
to-cytosolic ratio of KChIP2 in hearts from 5 ouabain-treated and 4 saline-treated mice and compared with 
Student’s t test.
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We transfected cells with the Ca2+-insensitive KChIP2-∆EF mutant to determine if KChIP2’s Ca2+ sensitivity 
is responsible for translocation. There was no difference in KChIP2 localization between control cells and cells 
treated with Ca2+ ionophores in medium containing a physiological level of Ca2+ (Fig. 4). These experiments 
corroborate the in-vivo studies and show that KChIP2 is present in the nucleus of transfected, un-stimulated cells 
and they suggest that increases in intracellular Ca2+ concentrations do not trigger a translocation of KChIP2 from 
the cytosol into the nucleus in heterologous expression systems.
Localization of KChIP2 in Ca2+-depleted cells. KChIP2 localization in the nucleus in absence of 
stimulation indicates that the Ca2+ concentration during normal conditions is already elevated to a level that 
allows translocation, or that KChIP2 is independent of a raise in the intracellular Ca2+ concentration in order 
to translocate to the nucleus. To test this, we observed protein localization in a Ca2+-free environment. HL-1 
cells overexpressing KChIP2 were incubated for 40 min in a Ca2+ free medium and treated with A23187 in order 
to deplete intracellular Ca2+ (Fig. 5). The variations within both groups were large, but on average the nucleus/
cytosol ratio did not differ in Ca2+-depleted and control cells. Thus, the presence of KChIP2 in the nucleus is not 
regulated by Ca2+.
KChIP2 DNA binding studies using the Cacna1c promoter region. To test if KChIP2 regulates 
gene expression in general, we performed expression studies. If KChIP2 is an important transcript factor 
in vivo, we expect that transcription of a large number of genes would be altered. Microarray data detected 
the expression of 14,905 genes in the WT mouse hearts; however, only 37 genes were expressed with a statis-
tically significant difference in KChIP2−/− hearts that exceeded a 1.4 fold cut-off (Table 2). Figure 6 depicts 
the expression levels of membrane and ion-channel proteins in WT and KChIP2−/− hearts. Most changes in 
gene expression are very minor and involved mostly genes which were detected near background levels (log2 
values below 5), indicating that KChIP2 is not a transcriptional modifier. Finally, the microarray confirmed 
that KChIP2 is the only KChIP isoform expressed in the heart, and showed that no other KChIP isoform is 
expressed in KChIP2−/− hearts (Fig. 6).
The Cacna1c promoter region contains a Downstream Regulatory Element, a reported KChIP3 binding site21, 
whereby KChIP3 can repress transcriptional activity. In the microarray analysis, there was no difference in expres-
sion levels of Cacna1c in WT and KChIP2−/− hearts. To confirm the finding that KChIP2 does now affect tran-
scription of this gene, we used a chromatin immunoprecipitation assay on neonatal mouse cardiomyocytes treated 
with Ca2+ ionophores and used the obtained DNA as a template for quantitative PCR. Despite using 2 different 
KChIP2 antibodies, the amount of precipitated input DNA was low relative to control, indicating that KChIP2 
Figure 3. KChIP2 localization in heterologous expression systems. (A) COS-1 cells transfected with KChIP2 
and treated with 0 μM and 10 μM ionomycin for 40 min. The extracellular [Ca2+] was 1.8 mM. Pictures showing 
representative cells stained using a KChIP2 antibody (green). The nucleus is stained blue using DAPI.  
(B) Graph showing the intensity of the KChIP2 and DAPI signals along the red line in panel A for the cell 
treated with 10 μM ionomycin. One hundred consecutive values were chosen within both the cytosol and 
nucleus for quantification of protein localization (indicated by red lines). (C) Quantitative analysis of the time- 
and concentration-dependency of KChIP2 translocation from the cytosol to the nucleus using ionomycin as a 
trigger. Five cells from each transfection (n = 4–5) were chosen for quantification and compared using a 1-way 
ANOVA.
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Figure 4. Regular KChIP2 (WT) and KChIP2-∆EF (∆EF) expression and localization in COS-1 cells. 
COS-1 cells transfected with WT KChIP2 and KChIP2-∆EF and treated with 10 μM ionomycin for 40 min. 
Pictures showing representative cells stained using a KChIP2 antibody (green). The nucleus is stained blue using 
DAPI. Both KChIP2 and KChIP2-∆EF are present in the nucleus.
Figure 5. Ca2+ depletion in HL-1 cells. (A) HL-1 cells transfected with KChIP2 cDNA and treated with 
0 μM A23187 in a Ca2+-containing medium or 10 μM A23187 in a Ca2+-free medium for 40 min. Pictures 
showing representative cells stained using a KChIP2 antibody (green). The nucleus is stained blue using DAPI. 
(B) Quantitative analysis of KChIP2 localization after Ca2+ depletion and the control. Five cells from each 
transfection (n = 2–3) were chosen for quantification and compared using a Student’s t test.
www.nature.com/scientificreports/
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does not bind to DNA under the present conditions. Thus, the present experiments show that KChIP2 does not 
function as a repressor of gene expression in vivo in the mouse and that KChIP2 does not bind DNA in vitro.
Discussion
Three proteins were described practically simultaneously, and we now know that these proteins are identical: 
Calsenilin was initially described as a calcium-binding protein that binds presenilin, which is critically involved 
in early-onset familial Alzheimer disease20. Downstream regulatory element antagonist modulator (DREAM) was 
described as a calcium-regulated transcriptional repressor of key genes involved in memory and pain19. Finally, 
the potassium-channel interacting proteins (KChIP) were described as important modulators of the neuronal 
A-type potassium current, which is comparable to the cardiac transient outward potassium current (Ito)11. Later, 
it was clear that calsenilin, DREAM and KChIP3 are the same.
In the heart, only KChIP2 is expressed. It significantly modulates Ito11,4,27,28, and recently we have identified 
direct functional interaction between KChIP2 and the cardiac calcium channel: KChIP2 binding to the cyto-
solic N-terminal domain of CaV1.2 causes a 40% increase in current amplitude8,13,15. KChIP1, 2 and 3 share 70% 
amino acid identity with an identical core domain containing 4 EF hands, of which 3 can bind Ca2+11. In neu-
rons, KChIP3 is upregulated in KChIP2−/− mice, and KChIP2 is upregulated in KChIP3−/− mice29, suggesting a 
compensatory expression profile displayed by the two proteins and potentially a complementary function. In the 
present study, none of the KChIPs are expressed in hearts from KChIP2−/− mice (Fig. 6).
In 2011, Ronkainen and colleagues21 identified a mechanism by which the calcium concentration of the cell 
could transcriptionally feedback on the calcium channel itself: A downstream regulatory element (DRE) in the 
Gene Symbol Mean WT Mean KChIP2−/− P value Ratio
Kcnip2 79.4 n.d. 0.00002 Only in WT
Olfr1284 35.4 n.d. 0.035 Only in WT
Igfals 38.0 n.d. 0.038 Only in WT
Mosc1 33.5 n.d. 0.018 Only in WT
Cdk2ap1 105.5 68.2 0.004 0.65
S100a9 63.4 41.2 0.031 0.66
Prp2 154.1 104.4 0.012 0.67
Myc 49.6 34.3 0.029 0.69
Cyr61 133.9 92.4 0.003 0.69
Ormdl3 76.6 54.0 0.003 0.70
Dear1 57.9 81.6 0.004 1.41
Mrps27 38.5 54.0 0.029 1.41
Amd1 242.8 341.6 0.015 1.41
Amd1 290.3 413.9 0.001 1.42
Wdr23 41.3 59.0 0.016 1.43
Foxo3 129.4 183.8 0.026 1.43
Myocd 86.2 123.4 0.001 1.43
Hmcn1 34.7 49.3 0.034 1.44
Dym 71.6 102.6 0.014 1.44
Otub1 84.4 122.1 0.011 1.45
Tfb2m 112.9 163.2 0.015 1.45
Pik3r1 259.6 378.1 0.045 1.46
Plxnb2 36.3 53.3 0.018 1.47
Ptgds 209.2 304.0 0.027 1.47
Max 232.3 337.7 0.035 1.47
Ddit3 86.4 127.6 0.033 1.48
Neb 47.7 71.9 0.042 1.49
Gmnn 85.2 127.4 0.001 1.49
Amd1 139.1 209.4 0.005 1.51
Ephx1 38.1 57.5 0.028 1.51
Rnf185 40.0 60.4 0.032 1.53
Gdap10 282.6 436.6 0.021 1.54
Gpx3 70.7 109.6 0.037 1.56
Pih1d1 n.d. 46.8 0.010 Only in KChIP−/−
Hdhd3 n.d. 47.2 0.039 Only in KChIP−/−
Ankrd45 n.d. 45.5 0.033 Only in KChIP−/−
Table 2.  Genes with significantly different and >1.4-fold changed expression in WT and KChIP2−/− 
hearts. n.d.: Not detected. P values from Student’s t tests.
www.nature.com/scientificreports/
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promoter region of Cacna1c was sensitive to CaMKII-mediated repression of transcription. When CaMKII was 
activated by rising cytosolic [Ca2+], KChIP3 would translocate from the cytosol to the nucleus, bind to the DRE 
and repress transcription of Cacna1c, the gene encoding CaV1.2, the cardiac calcium channel. Based on the overall 
similarity between KChIP2 and -3 and given the physiological expression of KChIP2 in the heart, we decided to 
test the hypothesis that KChIP2 was transcriptionally active.
KChIP2 is palmitoylated at the N-terminal which causes effective localization of KChIP2 to the cytoplasmic 
side of the plasma membrane and is required for achieving the full effect on Ito in heterologous expression sys-
tems30. Palmitoylation is the addition of palmitic acid derivatives to cysteine residues, and it has been suggested 
that it may not serve as a targeting signal per se, but rather stabilize the ion channel complex at the cell surface30. 
Both KChIP2 and -3 has a comparable cellular distribution, with clear staining in both cytoplasm and in nuclei 
in primary neuronal cultures18. In the present study, we show that KChIP2 can be identified in nuclear protein 
fractions from cardiac tissue from humans and from mice, and we show by immunofluorescence that cell lines 
transiently overexpressing KChIP2 have immunoreactive protein in the nucleus.
Figure 6. Expression of genes encoding membrane and ion-channel proteins in WT (n = 3) and KChIP2−/− 
(n = 3) hearts using the Affymetrix Mouse Gene 482 1.0 array. Colours indicate log2-transformed and mean 
normalized expression levels from high (red) to low (blue) shown in pseudo colours of the z-score (standard 
deviations from the mean). *P < 0.05 (Student’s t test). †Gene not expressed above the level of background noise 
(indicated for genes with statistically significant differences only). Integrin α-9 (Itga9) and the β2 subunit of the 
L-type Ca2+ channel (Cacn2b) were expressed at 82% and 135%, respectively, in KChIP2−/− hearts, relative to 
WT. KChIP2 was not detected in KChIP2−/− hearts.
www.nature.com/scientificreports/
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From the present study, it is clear that KChIP2 is present in the nucleus; however, it is unclear what func-
tion the protein has there, far from its described interaction partners at the cell surface. Small molecules 
and proteins up to a weight of ~40 kDa can passively diffuse through the nuclear pore complexes31, which 
could suggest that KChIP2 (32 kDa) is merely present in the nucleus as a consequence of non-regulation. 
Nevertheless, the documented regulation of the nuclear import of KChIP3 (28 kDa) is a clear example of 
a small, transcriptionally active protein that is actively transported to the nucleus when cytosolic calcium 
increases.
Using a host of stimulation protocols in vivo and in vitro, we were unable to unequivocally initiate a trans-
location process stimulating the transport of KChIP2 into the nucleus. Moreover, microarray data from 
KChIP2−/− hearts suggested that KChIP2 was transcriptionally inactive and the ChIP assay failed to show spe-
cific KChIP2-DNA interaction. Hence, based on these experiments, we conclude that unlike KChIP3, the nuclear 
presence of KChIP2 is not regulated by cytosolic calcium concentrations and KChIP2 does not interact with 
the DRE’s to repress transcriptional activity. One important limitation of the ChIP assay is that it is very useful 
for detecting proteins that binds DNA; however, it is not very specific in discriminating false negative and true 
negative outcomes.
The data shows that KChIP2 does not directly regulate transcription; however KChIP2 augments both sar-
colemmal K+ currents4,11,12 and Ca2+ currents8,13,15,32 with complex impact on action potential morphology8,32. 
This may set the stage for an electrical-transcriptional feedback loop, where current amplitudes and membrane 
potentials signals to the nucleus, which have been described previously, e.g., during atrial arrhythmias33. Thus, 
changes in KChIP2 levels may cause cardiac remodelling via this electrical-transcriptional coupling; however, a 
direct effect of KChIP2 on transcription is not likely.
Soltysinska and colleagues16 have previously shown that KChIP2 mRNA and protein levels are significantly 
reduced in ventricular tissue samples from end-stage heart-failure patients (New York Heart Association class IV). 
In the present study, we found a surprising trend (P = 0.064) towards upregulated total KChIP2 protein in sam-
ples from failing hearts (Fig. 1C). Heart samples and sources differed in the two studies; however, the primary 
antibody was identical. The age of the healthy donors may have contributed to the difference in results, as our 
donors were older (59 years of age versus 42 years of age in the Soltysinska study) and thereby potentially had 
lower KChIP2 expression. It is clear that we need larger and better controlled studies of the proteomic changes 
that occur in the heart with disease and with age. Notwithstanding, KChIP2 may not be unequivocally downreg-
ulated in heart disease.
In conclusion, we show that KChIP2 does not translocate from the cytosol to the nucleus in a regulated man-
ner and that KChIP2 cannot bind DNA or modulate gene expression as a conventional transcription factor. The 
potential function of nuclear KChIP2 is presently unknown. Moreover, our data suggest that the general assump-
tion that KChIP2 reduction in heart failure is the primary electrophysiological hallmark of the disease may not 
be universal.
Methods
Ethical considerations and experimental animals. Human left ventricular tissue was harvested from 
end-stage failing hearts removed during heart transplantation or from donor hearts not suitable for transplanta-
tion as approved by the Local Ethics Committee (Ref No. 20–277 ex 08/09) of Medical University of Graz, Austria. 
All procedures were carried out in accordance with the approved guideline and the patients had all provided writ-
ten informed consent. None of the donors had a clinical history of heart failure and were classified as non-failing 
with preserved ejection fraction according to echocardiographic assessment before explant.
Animal experiments were performed using male C57BL6 (wild type) and KChIP2−/− mice. Mice were gen-
otyped (GeneTyper, NY, USA) using DNA isolated from tail samples. Animals had access to water and food ad 
libitum and were housed in a room with a temperature of 22 °C and a 12 h light/dark schedule. Body temperature 
was kept at 37 °C during surgical procedures. Euthanasia was done by cervical dislocation at the end of the exper-
iments. The experiments were approved by the national ethics committee (The Ministry of Food, Agriculture and 
Fisheries, Denmark) and were carried out in accordance with the approved guidelines. Further, the experiments 
conform to The Council Directive of the European Communities on The Protection of Animals used for Scientific 
Purposes (2010/63/EU) and the declaration of Helsinki.
KChIP2 localization in vivo. Mice were anesthetized with 1.5% isoflurane and surface ECG and core 
temperature was monitored throughout the experiment. Adrenaline (2 μg/g) and caffeine (120 μg/g) was 
co-administered intraperitoneally (IP) in order to raise the intracellular Ca2+ concentration in the cardi-
omyocytes. In addition, dobutamine (2 μg/g IP), ouabain (1 mg/g IP or 60 μg/min intravenously (IV)) or 
isoprenaline (2 μg/g IP) were tested. Mice injected with saline served as control. The hearts were explanted 
after 10 minutes treatment and snap frozen in liquid N2. Tissue from human and mouse hearts were stored 
at −80 °C until use.
The tissues were homogenized using Precellys system (Bertin Technologies, France) and the proteins were 
isolated and divided into cytosolic and nuclear fractions using NE-PER fractionation kit following the manufac-
turer’s instructions (Thermo Scientific, MA, USA). Total protein concentration in the samples was determined 
using a Lowry protein assay (BioRad, CA, USA). Human and murine samples were separated on 4–15% TGX 
SDS-PAGE or 4–20% Tris-HCl SDS-PAGE (BioRad), transferred to immobilon hybond-p polyvinylidene flou-
ride (PVDF) transfer membranes (Millipore, MA, USA) and blocked in Odyssey blocking buffer (LI-COR, NE, 
USA). The membranes were blocked in 4% milk in PBS. Primary antibody incubation was done overnight at 4 °C 
using a KChIP2 antibody (3.47 μg/ml, NeuroMab, UC Davis, CA, USA). Lamin A/C antibody (Cell Signaling 
Technology, MA, USA) was used to test if the fractionation protocol was successful, as lamin A/C is confined to 
the nucleus. GAPDH (0.2 μg/ml, Sigma-Aldrich, MO, USA) and β-tubulin antibodies (1 μg/ml, Millipore, MA, 
www.nature.com/scientificreports/
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USA) served as loading control: Total (nuclear + cytosolic) content should be comparable between subjects; how-
ever, it is not possible to compare protein loading between cytosolic and nuclear lanes. Immunoreactive proteins 
were detected using fluorescent donkey anti-mouse and donkey anti-rabbit antibodies (0.1 μg/ml, LI-COR, NE, 
USA), or with peroxidase conjungated donkey anti-mouse and donkey anti-rabbit antibodies (0.08 μg/ml, Jackson 
Immunoresearch, PA, USA). Visualization of the proteins was done using the Odyssey system (LI-COR, NE, 
USA) and enhanced chemiluminescence for human and murine samples, respectively. Each sample was tested in 
duplicate. Densitometric quantification of the bands was performed with the Image Studio (LI-COR, NE, USA) 
and ImageJ software.
KChIP2 translocation in vitro. Experiments were performed using COS-1 cells cultured in Dulbecco’s 
Modified Eagles Medium (DMEM) containing 10% Fetal Bovine Serum (FBS) and 1% penicillin-streptomyocin, 
and HL-1 cells cultured in Claycomb medium (Sigma-Aldrich, MO, USA) supplemented with 2 mM L-glutamine, 
100 μM noradrenaline, 10% modified FBS and 1% penicillin-streptomyocin. COS-1 and HL-1 cells were 
plated in 35 mm dishes in DMEM and Claycomb medium, respectively, for 24 hours and transiently trans-
fected using SilentFect (Invitrogen, CA, USA) according to the manufacturer’s instructions. Human KChIP2.1 
in a pXOOM vector was used for transfections. In some experiments a Ca2+-insensitive KChIP2 mutant 
with asparagine-to-alanine substitutions in the Ca2+-binding EF hands (KChIP2-∆EF) was used to probe 
calcium-dependency of translocation15.
Transfected COS-1 cells were treated with either 0, 1 or 10 μM ionomycin for 0, 10, 20 or 40 min or with 0 or 
10 μM A23187 (Sigma-Aldrich) for 0 or 40 min, in order to elevate the intracellular Ca2+ concentration. The Ca2+ 
ionophores were dissolved in DMSO and diluted in DMEM to reach final concentrations. Moreover, HL-1 cells 
were treated with 10 μM A23187 in Ca2+ free DMEM for 40 min. Cells treated with DMSO in Ca2+-containing 
DMEM served as control. In both experiments the cells were fixed in 4% paraformaldehyde for 20 min. KChIP2 
was stained using a KChIP2 antibody (10.4 μg/ml, NeuroMab) and fluorescent secondary antibody (4 μg/ml, 
Alexa Flour 488 donkey anti-mouse, Invitrogen) and the nuclei were stained using 4′,6-diamidino-2-phenylindole 
(DAPI, 16.7 μg/ml). Protein localization was visualized using confocal microscopy (LSM710, Zeiss) and ImageJ 
software was used to quantify the fluorescent signal across the cell. This was done by drawing a line through both 
the nucleus and cytosol, using the fluorescent signal intensities as a measurement for protein density. One hun-
dred consecutive values were chosen within both nucleus and cytosol, the values were averaged and a nucleus/
cytosol ratio was calculated.
Microarray analysis. Ventricular heart tissue from 3 wild type and 3 KChIP2−/− mice was used for the 
analysis. The tissue was homogenized using Precellys system, and from the homogenates the RNA was iso-
lated. NanoDrop Spectrophotometer and Flourospectrometer (both Thermo Scientific) were used for RNA 
concentration determination. RNA was amplified and labelled using a pico-amplification kit according to 
manufactures instructions. In short, 50 ng total RNA was amplified using the Ovation Pico WTA v.2 RNA 
Amplification System from (NuGEN, San Carlos, CA, USA) and biotin labelling was performed with the 
Encore Biotin Module (NuGEN). The labelled samples were hybridized to the Mouse Gene 1.0 ST GeneChip 
array (Affymetrix, Santa Clara, CA, USA). The arrays were washed and stained with phycoerytrin conjugated 
streptavidin (SAPE) using the Affymetrix Fluidics Station 450, and the arrays were scanned in the Affymetrix 
GeneArray 3000 7G scanner to generate fluorescent images. Cell intensity files (CEL files) were generated in 
the GeneChip Command Console Software (AGCC) (Affymetrix, Santa Clara, CA, USA) and imported into 
the software Partek Genomics Suite. The data was pre-filtered to exclude genes with an average expression 
level within each group (WT and KO) below noise or background level of log2 values of 3. Class comparison 
between the WT and KO was performed and a gene was defined to be differentially expressed between the two 
groups if p-value was below 0.05 in t-test and fold change above 1.4. For hierarchical cluster visualization of 
membrane proteins and ion channels, the average expression value for each of the two groups was imported 
into Qlucore Omics explorer v. 3.2 (Qlucore, NY, USA) and genes were normalized to have mean equal to 
zero.
Chromatin ImmunoPrecipitation (ChIP). Neonatal ventricular mouse cardiomyocytes were isolated 
1–2 days postpartum and cultured as described previously34. Cardiomyocytes were treated with 1 μM A23187 
(Sigma-Aldrich) or DMSO as control for 1 hour. Cells were fixed in 1% formaldehyde for 15 min at room tem-
perature, washed in ice-cold PBS, scraped in Farnham lysis buffer containing Protease Inhibitor Cocktail (PIC, 
Roche, Switzerland), centrifuged for 5 min at 700 g and pellets were snap frozen. Pellets were then resuspended in 
RIPA buffer containing PIC and sonicated to an averaged chromatin size of 200–300 base pairs using Bioruptor 
sonicator 4 × 10 min, followed by centrifugation for 15 min at 15.000 rpm. Both monoclonal and polyclonal 
KChIP2 antibodies (13 μg/ml for NeuroMab and 2.5 μg/ml for Santa Cruz Biotechnology, TX, USA) were used to 
immunoprecipitate protein-DNA complexes. Rabbit IgG was used as negative control while KChIP3 antibodies 
were used for positive control. The DNA was purified using QIAquick PCR Purification Kit (Qiagen, Germany) 
following the manufacturer’s instructions, and the DNA fragments used as template for quantitative PCR (qPCR). 
KChIP2 binding was examined using primers specific for the Cacna1c promoter region containing a Downstream 
Regulatory Element (DRE) sequence, which is a putative KChIP2 binding site, or for a negative control region 
about 1000 base pairs downstream from the binding site.
Statistical analysis. All data are presented as mean ± SEM. Statistical analysis were done with Student’s 
t-test or 1-way ANOVA for comparison of two groups or more underlying two variable conditions. P-values < 0.05 
were considered statistical significant.
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